Novo Nordisk to explore how GLP-1 drugs can help patients with addiction
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
Medical Marketing & Media1h
Novo, Lilly and Novartis lead pharma’s stellar ad performance at Oscars
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
BioSpace8h
Novo Enters the Ring in Legal Fight Against GLP-1 Compounders
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
Telehealth firms Teladoc, LifeMD tie up with Eli Lilly's pharmacy partner to offer Zepbound
Telehealth firms Teladoc Health and LifeMD said on Thursday they have signed an agreement with Eli Lilly's direct-to-consumer ...
Modern Healthcare7h
Teladoc, LifeMD partner with Eli Lilly on GLP-1s
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Novo takes ‘direct shot’ at Hims & Hers with NovoCare , says Citi
Citi analyst Daniel Grosslight keeps a Sell rating on Hims & Hers (HIMS) with a $27 price target after Novo Nordisk (NVO) announced ...
Novo Nordisk to sell Wegovy for $499 a month to cash-paying US customers
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...
'For Novo Nordisk, I do not worry a lot about tariffs:' CEO Lars Jørgensen
Novo Nordisk (NVO) is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical companies next week. CEO Lars Jørgensen told reporters Thursday, "For Novo ...